CPT code 19100 represents a percutaneous core needle biopsy of a breast lesion used to obtain tissue for histopathologic diagnosis, often to evaluate for breast cancer. This procedure is a common diagnostic step in the evaluation of suspicious breast masses and has national relevance for cancer detection pathways, quality metrics, and care coordination between radiology, surgery, and pathology.

Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context for 19100, typical sites of service, and payer relevance. The publication outlines what stakeholders can expect to learn about payment benchmarks, coding and billing considerations, and policy updates affecting coverage and utilization for breast core needle biopsy.

The content is aimed at clinicians, billing professionals, and policy analysts seeking a clear reference on the intent and clinical use of CPT code 19100, how it fits into diagnostic workflows for suspected breast cancer, and the payer landscape that commonly reimburses this service. Data not provided in the input, such as associated taxonomies, specific ICD-10 diagnoses, and related codes, are noted as unavailable elsewhere in the document.